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Immunological surveillance is the term used to describe part
of the immune system's general function of recognising and destroying
foreign protein and polysaccharide when the foreign substance is
derived from what were normal body cells. These cells can be altered
by a variety of factors uncluding somatic mutation, chemicals, viruses
and irradation, agents classically associated with carcinogenesis. In
fact the idea of immunological surveillance really arose from
consideration of some of the immune phenomena associated with clinical
and experimental tumors.
The evidence includes tumor histology with lymphocyte and plasma
cell infiltration; the demonstration of tumor immunity and tumor
specific antigens; experimental work on neonatal and adult mice in
tumor induction; statistical analyses of tumor incidence in cases of
immunological disorders and the success of therapeutic means aimed at
augmenting the destruction and recognition sides of the system.
I have approached the presentation of this evidence in terms of
what one would theoretically expect the properties of the system to
be for it to be valid.
The great attraction of the concept is that it provides a
stimulating and fresh outlook on the problem of CANCER, suggesting
«
various experiments which modern developments in technique and equipment
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will allow for the first time. Its appeal to the clinician is its
immunological basis with the resurrection of Almroth Wright and his
early 1900's belief that immunotherapy aiding the body's own defences
would be the means of curing all ills.
The concept has taken shape in the last twenty years. Therapeutic
possibilities suggested by it have been tried out on animals. Some
considered the results encouraging enough to attempt the same in man.
Their successes and failures I shall describe and discuss in a later
section of this essay.
Immunological surveillance is thought of as the latest develop¬
ment in the evolution of adaptive immunity. Invertebrates lack anti¬
body production or any of the other characteristic features of the
mamalian immune system. However they do have a protective response
against the entry of foreign organisms or material through phagocytic
cells. Primitive vertebrates e.g. hagfish are very similar to the
invertebrates but the lamprey can produce limited antibodies, has a
primitive thymus and will reject homografts. All the higher fishes
show immune responses which are much more specific. Amphibia and
reptiles are similar. The increase in body temperature increases the
speed and effectiveness of the immune responses.
The stimulus to the development of a surveillance mechanism is
though' to be that increase in animal size and length ol survival meant
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an increased risk of somatogenetic changes in cells and hence an
increased risk of aberrant cells developing. I shall describe in
detail the cellular system which evolved to meet this challenge.
CONCEPT;-
Immunological surveillance is a term used to describe the
state of affairs in which aberrant cells possessing a foreign antigen
induced by radiation, mutation, viruses or chemicals, may evoke a
homograft type reaction with resulting destruction. It is particularly
applied to tumor cells in which a breakdown of this system allows an
abnormal clone of cells with a selective advantage over other cells
to develop.
BASIC IMMUNOLOGICAL PROBLEMS of the concept are many
(1) The recognition problem -
(a) What are the cells involved? : lymphocyte and macrophage
(b) How do these cells recognise
and respond to antigen? : surface antibody (Ab)
(c) Do tumor cells have new
antigens? : Yes (some do)
(2) The destruction process -
(a) What are the consequences lymphocyte proliferation
of lymphocyte interraction : and tumor cell destruc-
with tumor cell antigen (Ag) tion.
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(b) The interactions of lymphocyte
and macrophage in destruction
of tumor cells
(c) The part played by cytotoxic
Ab in destruction : - little
Why do tumors survive? ; logically a failure of any element of the
recognition or destruction system.
- also the concept of 'tolerance'.
Epidemological evidence pertaining to immunosurveillance in man.
Therapeutic possibilities and : (l) Improve recognition
procedures carried out to date (2) Improve destruction
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THE RECOGNITION PROCESS
(a) The cells involved:
The theory of immunological surveillance requires a
highly efficient and sensitive recognition system. At present it
is believed that the lymphocytic and to a lesser extent the macro¬
phage cell systems represent a cellular component of such a system.
Lymphocytes vary both morphologically and functionally. Large
lymphocytes are actively dividing lymphocytes of uncertain origin
which are often found in the stroma of the villi of the small intestine.
They can resemble immature plasma cells or divide to give rise to
small lymphocytes. They resemjole small lymphocytes in the early stages
after stimulation by antigens to undergo transformation.
Small lymphocytes are identical under the light microscope but
vary in life cycle and function and origin.
Long-lived lymphocytes are derived from a stem cell in bone
marrow which populates the lymphoid tissue of the gut and associated
structures and the thymus. In the thymus these stem cells differentiate
to lymphocyte precursors which divide to give rise to small lymphocytes.
Some of these small lymphocytes leave the thymus and populate the gut
associated lymphatic tissue, especially the paracorticrel zones of
lymph nodes and around the central artery of the fflalpighian bodies of
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the spleen. The lymphocytes in these areas neither die or divide
but circulate freely in the blood stream. These thymic lymphocytes
produce the cell mediated immune reaction which destroys tumor cells
as well as playing a part in the recognition system.
Short-lived small lymphocytes are thought to arise from the bone
marrow cells which populate the gut associated lymphatic tissue directly.
It is thought they are the progenitors of lymphocytes which are in turn
the precursors of antibody - forming cells found in the medulla of
lymph nodes and spleen.
In summary - the lymphocytes involved in the recognition part of
immunological surveillance are long lived uncommitted lymphocytes
derived from the thymus. They are sometimes known as immunocytes -
cells of one genetic capacity which will form clones when they meet
up with the appropriate antigen.
The macrophage system is made up of cells differing morphologically
and functionally. They phagocytose particulate material in the
circulation including antigen. Soluble antigen they engulf by
pinocytosis. Macrophages are found in many tissues but especially
liver, lung, spleen and lymph nodes. Some are tissue fixed probably
derived from precursor cells in the tissue, while others are actively
motile and found in the blood. Those of importance in the recognition
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of tumor cell antigens are found alongside lymphocytes in the gut
associated lymphoid tissue and in the thymus.
How do these cells recognise and respond to antigen? :
The thymic long-lived small lymphocyte (immunocyte) is capable
of producing at the most three different antibodies by genetic limit¬
ation. Samples of these antibodies are to be found bound to the
surface of the immunocyte. Thus when the specific antigen comes into
contact with this immunocyte Ag - Ab binding will take place. The
immunocyte responds by blast transformation replicating itself and thus
increasing the recognition of similar antigens on other adjacent cells.
However the question arises - does the immunocyte go to the antigen
or does the antigen come to the immunocyte. This problem has theor¬
etical implications concerning tumor survival and will be discussed in
a later section.
The macrophage also has antibody on its cell surface, taken up
passively as it has a function catabolising antibody. Thus it is
capable of fixing antigen which is itself structural e.g. part of a
cell wall. Blood macrophages unlike lymphocytes are freely motile
cells capable of passing through capillary membranes into the tissues.
They are therefore theoretically capable of recognising cell fixed
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antigen outwith the blood stream and free antigen in the blood
stream. The macrophage response is thought to be formation of an
flRNA complex with antigen which can act on lymphocytes causing them
to divide, become cytopathic and destroy the antigen or cell it is
part of. Surface fixed antigen can also act as a long term stimulus
to antibody formation by lymphocytes in the medulla of lymph nodes.
The importance of these cells to modern evaluation of a tumor's
pathogenicity and the patient's prognosis is great. Often there are
considerable differences in the extent to which there is a round-celled
reaction at the edge of the tumor mass. Often plasma cells are
conspicuous among lymphocytes and macrophages. Two studies to correlate
cti-vecT
the intensity of round-celled response with survival showed a*
correlation.
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Do tumor cells have new antigens?
There have been two approaches to answering this question.
The first entailed showing that there was a gross immune response
against tumor cells, the assumption being made that as the body's
immune system does not react against the host's tissues any evidence
of an immune reaction would be due to new tumor specific antigens.
The methods used included prior immunisation by
(a) transplanting a tumor from one animal to another and
removing it surgically after it had reached a certain size.
(b) injecting irradiated tumor cells which are still metabolising
normally but are incapable of division.
(c) 'immunising' an animal with a dose of tumor cells too low
to cause a tumor.
That immunity is produced by these means is shown by the evidence
that when these animals are then subject to a dose of tumor cells
sufficient to cause a tumor, the cells are destroyed whereas a similar
dose in unimmunised animals causes a tumor in every case.
It was believed at first that tumor cells were de-differentiated
cells which had lost antigens and this was shown experimentally but
gradually evidence for the formation of 'new' antigens accrued.
Chemical carcinogens producing different tumors in the same animal
species mere shown to produce different antigens in each tumor while
viral induced tumors though structurally different were found to have
the same viral specific antigen. Chemically induced tumors tend to
differ very widely in their immunising capacities.
The second approach utilised the tools of diagnostic serology
and as such was more applicable to man. Virtually all the work
described above refers to animal experimental tumors. Evidence for
tumor antigens in man includes the following -
(1) Indirect evidence through complement fixation tests
detecting antibody to a tumor suspension acting as antigen. (However the
possibility of antibody being made in response to inaction and necrosis
of tumor cells still exists). Graham«Graham tested the sera of 48
cancer patients (tumor types unknown to me) in this way and got titres
of 1 in 16 to 1 in 128 with the most advanced cases lacking circulating
antibody.
(2) Antibody reactions were also elicited by the following
crocedures -
(a) irradiation or intra muscular injection of whole tumor
antigen with adjuvant (Finney, Byers and Wilson) in twelve
out of fourteen patients with a wide variety of tumors.
(b) Greensham, Brown and Schwartz showed that extracts of
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tissues from human leukaemias and Hodgkin's disease
injected into man gave an antibody response not induced
by similar extracts from non-leukaemic tissues.
(3) Immunofluorescence has been used to show antibody attached
to tumor cells in 30% of cases of malignant melanoma. It has also
been shown that there was cross-reactivity between melanoma cells
and the sera from a number of different melanoma patients (fluna et al).
Thus limited evidence is available for 'new' tumor antigens.
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THE DESTRUCTION PROCESS
(a) The parts.played by the lymphocyte and macrophage.
The immunoblast is formed by
(1) Antigen contact with antibody on the small lymphocyte
(uncommitted immunocyte) surface.
(2) Passage of a MRNA - Ag complex from the macrophage.
The immunoblast divides to form a clone of cytotoxic committed
immunocytes which are capable of destroying the cell whose Ag they
are committed against and a clone of plasma cells which can produce
antibody. (Whether this Ab is cytotoxic or not is often unknown).
The dendritic macrophages and lymphocytes inter-react in a complicated
manner to achieve the formation of these cell populations.
As more is known about this destruction process and because of
its possible manipulation for therapeutic purposes I shall describe it
at some length.
The process is similar to delayed type hypersensitivity -
In SUMMARY (l) lymphocytes and macrophages are effectors of the
reaction and affected by it.
(2) Sensitisation to an antigen can be transferred by
whole lymphocytes and macrophages or TRANSFER FACTOR
(? the RRNA - Ag complex mentioned previously).
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(3) Transfer factor causes lymphocytes to secrete many
other protein factors.
(4) Sensitised lymphocytes will transform in antigen
presence to produce more lymphocytes and also acquire
the capacity to kill by contact.
(5) The role of the macrophage though less clear appears
to be
(1) to initiate transfer factor formation
(2) to initiate antibody formation by the lymphocyte
(3) to be subject to an antibody feed back which
inhibits them and can thus diminish the destruction
process.
Antigen activation of sensitised lymphocytes results in the synthesis
and release by these cells of soluble cell-free factors. They are
called LYPIPH0KINE5 and include
(1) pyrogen : responsible for the immune 'fever' of many
conditions
(2) macrophage inhibiting factor (FlIH) : localises macrophages
at the site of the reaction.
(3) mitogenic factor (PIF) : stimulates non-sensitised recipient
lymphocytes to transform. This will increase the
size of the cytotoxic reaction but may result in
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the destruction of nearby cells which lack the
initiating antigen.
(4) cytopathic factor (CF : lymphotoxin) : this substance has
been shown to be cytotoxic for mouse fibroblasts
in monolayerculture. It may also increase the
permeability of blood vessels in the area to mono¬
nuclear cells by destroying vascularandothelium,
thus amplifying the immunological reaction.
(5) chemotactic factor (CWF) : again amplification of the response.
These factors are of molecular weight 80-50,000, protein, and
act independently of antigen; classical antibody and antigen - antibody
complexes (Dumonde et al 1969). Other factors which have been
described as being released in identical experimental models are a
material which is chemotactic for monocytes (Ward & David 1969) and a
material which promotes macrophage pnagecytosis (Barnet, Pekarek &
Oohanovsky 1968).
Antigen activation of sensitised lymphocytes also gives these
lymphocytes the capacity to kill specific target cells on contact.
They alter the osmotic equilibrium of these cells, which swell and
burst.
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Antigen affects MACROPHAGES by
(1) initiating transfer factor secretion : lymphokines produced
(2) increasing intracellular killing
(3) in a secondaiy manner, via lymphocytes and macrophage
inhibiting factor.































An outline such as the above serves to illustrate the key
areas in which therapy may theoretically be applied. Applications
will be discussed in the therapeutic part of this essay.
The part played by Antibody in destruction -
Antibodies can be cytotoxic or cytophilic, the distinction
being related to the capacity to fix complement.
Cytophilic antibodies;
(1) coat macrophages and allow them to become cytotoxic.
(2) coat tumor cells and possibly block destruction of
these cells by preventing cytopathic lymphocytes from
fixing to these cells.
Cytotoxic antibodies can destroy tumor cells in their own right.
However their concentration inside solid tumors is much less than their
concentration in plasma. It appears that they function best in the
elimination of blood metastases from tumors.
Some evidence for these ideas is found in studies done on
patients with malignant melanomas.
(1) Distant metastases were found only in those patients with
no antibody.
(2) Spread is by the local lymphatics if antibody is present
in the blood but by the blood only when antibody is absent.
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TUC'IOR GENESIS and SURUIl/AL
Tumors can arise
(1) Spontaneously due to genetic copying errors
(2) Through extraneous radiation damage
(3) From chemical carcinogens
(4) From viruses
That they survive is presumably due to failure of any element of
the recognition or destruction system.
e.g. failure of the recognition
system could be due to:
failure of destruction:
(1) lack of tumor specific Antigen.
(2) failure of macrophage to take
up antigen due to
(a) no ag. in the system
(b) no Ab on macrophage surface
(c) Blockade of the system
(3) No reciprocal antibody producing
uncommitted lymphocytes.
(1) failure of proliferation i.e.
no cytotoxic cells produced
(2) failure of access to tumor
(3) enhancing antibody hiding tumor
specific surface antigen.
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Th e phenomenon of TOLERANCE and its relevance to tumor survival.
Tolerance is the lack of reactivity of the body's immune
mechanisms to an antigen. The concept best explaining it is the clonal
selection theory of Wacfarlane Burnet in which the cells which should
respond to a particular antigen have either been inactivated or do not
exist.
1. INACTIVATION: this has been shown experimentally to occur in
response to very low or very high doses, of antigen. There appears to
be an intermediate dose range where an immune response is obtained.
A tumor of low or very high antigenicity could paralyse the immune
system in a similar manner. However often the continued presence of
antigen is necessary to prolong tolerance. This would rationalise
surgical removal of as much tumor tissue as possible with radio or
chemo therapy to destroy residual cells, thus reducing antigen concen¬
tration and hopefully reversing tolerance.
Whether surgery by dissemination of large numbers of tumor cells
actually induces tolerance is debatable. A tumor of low antigenicity
could have its blood antigen concentration brought into the dose
response range and thus aid the immune-response. It would appear that
most tumors are of this low antigenicity type.
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2. Lack of specific cells as the reason for tolerance might occur
in the following situations
(1) following excessive radiation 'treatment'
(2) following excessive chemotherapy
(3) following tumors of lymphoid tissue
(4) because the adult thymus is impermeable to 'self' antigens and
no immunocytes to these antigens are produced.
The relevance of tolerance to tumor survival is uncertain because not
enough is known of the body's cellular state and the immunology
involved.
An alternative approach was that adopted by Hellstrom in which
surveillance is regarded as a local phenomenon involving different
histo compatibility antigens between adjacent cells and not immuno¬
logical. However Flintz succeeded in producing an 'allophenic' mouse
by embryological manipulation and fusion of early embryos of two
distinct histocompatibility types. Mice produced in this way show
complete tolerance to and between both types of cell.
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EPIDEMIQLOGICAL EVIDENCE PERTAINING TO IFIMUNQSURVEILLANCE IN MAN
Medicine and statistics have both reached the sophisticated state
of being able to provide evidence pertaining to immunosurveillance in
man. The discovery of immunological deficiency diseases involving
cell mediated immunity; the operation of thymectomy for thymoma or
myasthemia gravis; immunosuppression in some auto immune diseases but
also for organ transplantation;and the age distribution of cancer have
all been subject to statistical analyses of the consequences. The
following evidence has been uncovered.
(1) IMMUNOLOGICAL DEFICIENCY DISEASES -
congenital types
(1) Ataxia telangiectasia - immunological deficit involves
defective cellular immunity and antibody response to antigen;
abnormalities in the level of serum ummunoglobulin and in the
thymus -
200 cases : 14 malignant tumors : 9 of which involved the
reticuloendothelial or lymphocytic systems
(2) Wiskott-Aldrich syndrome - 'numeral and cellular immunity
involved -
90 cases : 11 malignant tumors : mainly reticuloendothelioses
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(3) Chediak:Higashi syndrome - precise defect unknown
50 cases : 11 malignant tumors : mainly lymphomas
/ \ ^
(4) Agammaglobulinaemia and hypogammaglobinaemia -
high tumor incidence : variety of tumors
In general the tendency has been for a significant increase in tumors
in these people but particularly the reticuloendothelioses. However
the number of people involved is very low and often the precise nature
of the immunological defect has been in doubt.
It has also been suggested that the high incidence of lymphomas
and perhaps also of carcinomas in gluten enteropathy and cancers in
ulcerative collitis could have an immunological basis if it is
accepted that these disorders are auto-immune in origin.
(2) THYMECTOMY :
Agenesis in children results in early death from infection. In
adults thymectomy is practised for myasthenia gravis and thymoma.
The evidence to date on a series of patients (419) with a follow up
period of 12.3 years is that the incidence of tumors is normal with
a normal distribution of types.
(3) IMMUNOSUPPRESSION -
Therapeutic immunosuppression is a relatively new technique brought
to prominence by organ transplantation. It includes
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(1) drugs (azathioprine and prednisolone)
(2) antilymphocytic serum
(3) splenectomy and thymectomy
Kidney transplantation has revealed
(1) remarkable destruction of tumor, inadvertently transplanted
from the donor's kidney, when immunosuppression was removed.
(2) a 50 fold increase in the number of reticuloses in trans¬
plant patients receiving antilymphocytic serum.
Of 4000 renal transplant patients 37 neoplasms have arisen, 15
of which have been reticulum cell sarcoma (12) or other lymphomas (3).
It appears that transplant patients will require a far longer
follow-up before we can tell whether the incidences of tumors other
than the lymphomas is increased.
(4) AGE DISTRIBUTION -
The immune system is thought to be at its weakest at the extremes
of life. These times coincide with the highest incidences of tumors,
excepting seminoma of the testis and some varieties of Hodgkin's disease
in young men and tumors of the uterus in middle aged rather than
elderly women. However statistical analyses of age incidences of other
diseases of the elderly show similar patterns to cancer.
Possibly all these diseases are manifestations of some process
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of ageing albeit even an tSKnmubiological process but the data presently
available doeriot allow us to come to any definite conclusions.
In conclusion: derangement of the immune system seems to give an
increased incidence only of tumors of the immune system. The lack of
data on whether intensive immunosuppression will give an increased .
incidence of other tumors is critical.
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THERflPEUTIC POSSIBILITIES AND PROCEDURES
IMPROVED RECOGNITION - The following possibilities exist.
1. Increase the antigenicity of the tumor
(a) by low level irradiation
(b) by linking other antigens to tumor cells to
increase the degree of recognition
(c) by increasing antigen release : say using lysosomal
enzymes jgjtrypsin and chymotrypsin
(d) by eliminating enhancing antibody, blocking
recognition and destruction.
(a) Low level irradiation is considered unneccessary when large doses
of X-rays will destroy tumor cells more efficiently. However this
destruction is not 100% and high doses do affect whatever immune
reaction there is.
(b) E. Klein considered he was increasing the antigenicity of a tumor
when he applied 2, 3, 5, tri-athylene iminobenzoquinone to a variety
of pre-malignant and malignant skin lesions in man. He achieved
resolutions of more than 95% of pre-malignant keratoses, superficial
basal cell carcinomas and squamous cell carcinomas in situ in 50
patients without recurrences for observation periods of up to 5 years.
However his studies on neoplasms of NQN EPIDERMAL origin showed
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either (l) challenge reaction to T.E.I.B. similar to normal cells
(2) no reaction at all.
These included malignant melanoma, adenocarcinoma of breast,
mesothelioma, lymphosarcoma, Hodgkin's and other lymphomas.
His method was to apply the compound to the tumor areas for
up to 2 weeks; then to apply the compound over the whole body area.
This usually resulted in the rapid destruction not only of visible
areas but of unsuspected areas as well. The healing process was
unimpaired by this method.
The compound Klein applied probably acted as a hapten and
bound to protein on the tumor cell surface, the complex then acting
as an antigen. He was eliciting a form of contact hypersensitivity.
The lesions he dealt with are all very sensitive to X-rays but his
method leaves the healing process unimpaired, a very important
consideration in treatment.
(c) The use of proteolytic enzymes to increase antigen release from
a tumor is feasible but at present unattempted, even experimentally.
(d) A method of eliminating enhancing antibody without affecting
cytotoxic antibody is unknown. If cytotoxic antibody is as unimportant
in tumor destruction as at present it appears to be then removal of
gamma globulin from the plasma could be attempted. The value of such
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a procedure has still to be verified experimentally. However, the
part actually played by enhancing antibody is unknown for virtually
all tumors; in malignant melanoma it has been shown to play no part.
2. Increasing the number of LYMPHOCYTES for recognition by
(1) transfusion from an isogeneic donor
(2) cell culture techniques
(3) radiation
The first can easily lead to a graft-versus host reaction and lacks
specificity. No adequate cell culture techniques have been devised
to make the second feasible and the third, radiation, is quantitatively
inadequate.
3. Increasing the number of MACROPHAGES for recognition
(1) BCG injections
(2) killed corynebacterium parvum
(3) inducing inflamation around the tumor
Injections of BCG or killed C. parvum are non-specific stimulators
of the R.E.S. increasing macrophage number. Their use by Mathe in
the treatment of leukaemia has been impressive. The macrophages
produced probably act both via recognition and destruction processes.
I shall describe their use by Mathe under methods of increasing
destruction.
Inducing inflamation around a tumor certainly brings macrophages
into the vicinity. For skin tumors Gorer found that following
infection the tumors sometimes disappeared. In man malignant melanomas
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may respond to vaccinia and basal cell carcinomas to painting with
dichloronitrobenzene.
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IMPROVED DESTRUCTION The following possibilities exist.
(1) Increasing the number of sensitised lymphocytes
(2) Increasing the number of sensitised macrophages
(3) Increasing the amount of cytotoxic antibody
(4) By employing other immunological phenomena such as
(a) florid delayed type hypersensitivity
(b) graft v. host reactions
1. Increasing the number of sensitised lymphocytes
(a) This can be done by injecting tumor cells into the site of
drainage of unaffected lymph modes elsewhere in the body. The
pyronjunophilic blast cells will appear in the lymph draining the
lymph mode between four and ten days after antigenic stimulation.
(b) Experiments have shown that cytotoxic lymphocytes can be
Obtained by mixing circulating small lymphocytes with tumor cells
in vitro. Cell separation can be done using the IBFi continuous
Blood Cell Separator. Presumably there are relatively high levels
of circulating uncommitted lymphocytes.
The importance of producing cytotoxic immune lymphoid cells
is that they have the capacity to traverse capillary beds and carry
the immune response into the extra vascular spaces. Non-cytotoxic
lymphoid cells are confined to the vascular channels. This is
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part of the recognition problem discussed before and indicates the
importance of tumor being able to release antigen into the circul¬
ation. These in vitro methods may bell become of great importance
in building up the body's cytotoxic immune lymphocyte population.
2. Increasing the number of sensitised macrophages
Macrophages are sensitised in vivo by the liberation of cytophilic
antibody from nearby lymphocytes which coats the surface of the
macrophages making them cytotoxic.
Thus the macrophage component could be increased by
(a) Increasing the number of macrophages in the area of a
tumor. This can be done by the methods outlined previously for
improving the recognition of tumors by macrophages, e.g. causing
inflamatory reactions around a tumor bacteria, viruses, chemicals.
or Using injections of macrophage inhibiting factor into a
tumor area to localise macrophages in that area. However the various
lymphokines have not been purified sufficiently to allow their
independent or even amalgamated use.
(b) Theoretically by exposing normal macrophages to spleen
cells from immune animals. These cells would release cytophilic
antibody to coat the macrophages.
Evans and Alexander have shown that macrophages play the main
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part in the rejection of mice ascitic leukaemias.
("lathe's conclusions from work on mice leukaemias were
(1) Generally tumor cells are immunotherapeutically more
active than BCG
(2) BCG and tumor cells given together are more active
than when each is given alone
(3) BCG is more active if given in several doses; leukaemic
cells are just as active when a single dose is given
as when several are given
5
(4) Active immunotherapy is effective only when 10 leukaemic
cells or fewer were grafted
He treated acute lymphoblastic leukaemic patients by first
giving them sequential chemotherapy and irradiation to reduce the
number of leukaemic cells to a minimum. He then divided his patients
at random into four groups
(l) no further treatment - all relapsed in less
than 130 days
(2) BCG
(4) BCG and leukaemic cells
(3) leukaemic cells
only 9 out of 20
had relapsed by 130
days
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There were no significant differences in the rates of relapse
in the individual immunotherapy groups.
3. Increasing the amount of cytotoxic antibody
Before discussing methods of doing this the concept of
enhancement of tumor growth should be discussed. It is known that
injecting an animal with serum from an animal with tumor and then
injecting tumor cells into this animal will cause the growth of
tumor much more rapidly than if no serum had been given. It is
believed that antibody coats the tumor cells and interferes with
the recognition process. However note that antibody is given before
tumor cells, a situation which does not arise normally.
Immune serum could be raised in animals against tumor cells
but the possibility of both cytophilic as well as cytotoxic anti¬
body being present is high and thus the possibility of enhancement
would appear to be high. There is also the question of whether the
tumor antigens would be strong enough to elicit a tumor specific
immune response.
Plathe has shown that enhancing antibodies do exist in patients
with choriocarcinoma. However malignant melanoma injections have
not been shown to produce enhancing antibodies in the patients
affected.
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UJhen adequate methods of separating cytotoxic and cytophilic
antibodies are found passive immunotherapy, as the technique of raising
an immune serum is called, should be useful against tumor cells.
4. The employment of immunological phenomena
(1) Florid Delayed Type hypersensitivity
This method depends on making a tumor more antigenic. Not
only does it increase recognition across several fronts, it also
allows destruction by a variety of clones of cytotoxic lymphocytes.
E. Klein's work on skin tumors was described in some detail under
methods of improving recognition. Its effectiveness indicates the
potential of this method.
Some of the anti-tumor drugs which act on nucleic acid synthesis
may exert part of their effect immunologically due to the alteration
in synthesis of some proteins which may be capable of acting
antigenically.
(2) Graft v. Host reaction
This reaction occurs when.cells of the lymphoid series are
grafted from one host to another who is immunologically different.
If enough lymphoid cells are grafted or if the host's lymphoid cells
are suppressed, then the grafted cells set up immunological reactions
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against the host's lymphoid tissue and his other body tissues
which are antigenic including any tumor he may have. Injections
of immune lymphocytes into immunosuppressed individuals gives a
florid graph versus host reaction but although the tumor cells are
partially destroyed so are the host cells.
The other approach has been to use specific immune lymphocytes
irradiated with lOOOr. which allows these cells to retain their
anti-tumor activity but stops them from dividing. There is no
possibility of a graft versus host reaction but the immune lymphocytes
can have an anti-tumor effect on their own. This technique could
be used in conjunction with tumor chemotherapy, part of whose
theoretically unwanted side effects has been the suppression of the
immune system.
In conclusion:
The cell system is there; new antigens exist end the body does
react against them but often inadequately. Perhaps we are asking too
much of the system to have it work perfectly all the time, to have
no inadequacies, no faults. Perhaps our changing environment is
bringing about somato genetic change so rapidly that as far as tumors
are concerned the defence system cannot cope. It does cope
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excellently with komografts and delayed type hypersensitivity,
much to our cost at times. However I think the system does have
enough potential to make immunotherapy worthwhile in treating
tumors although it appears that one must reduce tumor cell mass
as much as possible by conventional means before embarking.
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